Dong Jian, Dai Wen-da, Fang Tao-lin, Lin Hong, Uemura Toshimasa
Department of Orthopaedics, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zhonghua Yi Xue Za Zhi. 2007 Jan 16;87(3):190-4.
To investigate the effect of the immunosuppressant Tacrolimus (FK506) on the osteoblastic differentiation and in vivo osteogenic inducement of bone marrow-derived mesenchymal stem cells (MSCs).
MSCs were derived from Fischer 344 rats. Some MSCs were cultured with L-ascorbic acid-2-phosphate (AsAP) and beta-glycerophosphate (beta-GP) or FK506 plus AsAP and beta-GP. The alkaline phosphatase (APase) activity and calcium deposition were detected 4, 8, 12, and 16 days after the culture. Scanning electron microscopy was used to examine the calcified nodules. Northern blotting was used to detect the mRNA expression of osteocalcium. Multiparous beta-tricalcium phosphate (beta-TCP) ceramic cubes were dipped into 2 kinds of suspension of MSCs, treated by FK506 + AsAP + beta-GP or AsAP + beta-GP, so as to produce 48 pieces of MSCs/beta-TCP complex that were randomly divided into 2 equal groups to be cultured with AsAP + beta-GP or AsAP + beta-GP + FK506 for 4 weeks. The these pieces were transplanted into the subcutaneous sites of the rats' backs and were taken out 4 and 8 weeks later respectively for histological examination.
In vitro assays showed that the APase activity, calcium deposition, expression of osteocalcin mRNA of the FK506 + AsAP + beta-GP group at any time points were all significantly higher than those of the AsAP + beta-GP group (all P < 0.05). SEM showed that since the 16th day after culture calcified nodules began to be seen in the FK506 + AsAP + beta-GP group. Since the 4th weeks after transplantation remarkable new bone formation could be seen in the FK506 treated MSCs/beta-TCP complexes in comparison with those MSCs/beta-TCP complexes without treatment with FK506.
Greatly enhancing the in vitro osteoblastic differentiation and in vivo osteogenesis of MSCs, FK506 has a potential value as a bone growth factor and may improve the clinical result of bone transplantation used to treat large bone defect. The results of this experiment also contributes to a better understanding on the mechanism of immunosuppressants.
研究免疫抑制剂他克莫司(FK506)对骨髓间充质干细胞(MSCs)成骨分化及体内成骨诱导的影响。
MSCs取自Fischer 344大鼠。部分MSCs用L-抗坏血酸-2-磷酸酯(AsAP)和β-甘油磷酸酯(β-GP)或FK506加AsAP和β-GP进行培养。培养4、8、12和16天后检测碱性磷酸酶(APase)活性和钙沉积。用扫描电子显微镜检查钙化结节。用Northern印迹法检测骨钙素的mRNA表达。将多孔β-磷酸三钙(β-TCP)陶瓷块浸入2种MSCs悬液中,分别用FK506 + AsAP + β-GP或AsAP + β-GP处理,制成48块MSCs/β-TCP复合物,随机分为2等份,分别用AsAP + β-GP或AsAP + β-GP + FK506培养4周。将这些复合物分别移植到大鼠背部皮下,4周和8周后取出进行组织学检查。
体外实验显示,FK506 + AsAP + β-GP组在任何时间点的APase活性、钙沉积、骨钙素mRNA表达均显著高于AsAP + β-GP组(均P < 0.05)。扫描电子显微镜显示,培养第16天起FK506 + AsAP + β-GP组可见钙化结节。与未用FK506处理的MSCs/β-TCP复合物相比,移植后第4周起FK506处理的MSCs/β-TCP复合物可见明显的新骨形成。
FK506可显著增强MSCs的体外成骨分化及体内成骨能力,作为骨生长因子具有潜在价值,可能改善治疗大骨缺损的骨移植临床效果。本实验结果也有助于更好地理解免疫抑制剂的作用机制。